The civic record
Read. Follow. Verify.Promising Pathway Act 2.0: New Conditional Approval Process for Rare Disease Drugs
Record date · May 23, 2024
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
This bill creates a new, time-limited '' pathway for drugs intended to treat serious, rare, or rapidly progressive diseases. It requires patients taking these drugs to enroll in observational registries to track safety and effectiveness, and mandates that health insurance plans cover these drugs without for patients.
If passed, this bill would allow patients with rare or terminal conditions to access certain drugs before full FDA approval, while requiring insurers to cover the full cost of these treatments.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Patients with rare or serious diseases
Patients gain access to conditionally approved drugs and are required to enroll in observational registries to receive them.
Health insurance issuers
Insurers are required to provide coverage for these drugs without cost-sharing for patients.
Drug sponsors
Sponsors must establish observational registries, submit data to the FDA, and adhere to strict labeling and marketing requirements.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
Will my insurance cover these drugs?
What happens if the FDA withdraws approval for a drug I am taking?
Do I have to participate in a study to get these drugs?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently filed. The next step in the legislative lifecycle is Committee.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Shift toward Real-World Evidence
The bill explicitly mandates the use of real-world evidence and observational registries as a core component of the drug approval and renewal process, signaling a move away from relying solely on traditional clinical trials.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz25Current news / social attention level
Publisher tools